Why is AstraZeneca stock up today?
AstraZeneca's stock climbed 1.6% to 11,650p after announcing three promising Phase III trial results in non-small cell lung cancer (NSCLC). The most significant win came from the SAFFRON study, which demonstrated that the combination of Tagrisso and Orpathys, developed by partner HUTCHMED, led to improved progression-free survival and overall survival in EGFR-mutated NSCLC patients whose disease had progressed compared to standard platinum-based chemotherapy.
AstraZeneca's partnership with Daiichi Sankyo also reported positive news in the DESTINY-Lung04 Phase III trial, showing Enhertu outperformed in progression-free survival as a first-line treatment for HER2-mutant advanced NSCLC patients. However, the positive news was tempered by the discontinuation of the eVOLVE-Lung02 Phase III trial, which was testing volrustomig in combination with chemotherapy for metastatic NSCLC patients with low PD-L1 expression, as the independent data monitoring committee deemed the combination unlikely to achieve its dual goals.
Despite this setback, the two successful trials outweighed the negative and highlighted AstraZeneca's robust pipeline and resilience to individual trial failures. Broader market factors, such as a recovery in the FTSE 100 after a 1.4% weekly decline and softer US retail sales and producer-price data reducing expectations for near-term monetary tightening, also contributed to a more constructive environment for risk assets.
With a 52-week range of 10,784p to 15,730p, AstraZeneca's shares are still below their highs, meaning positive clinical catalysts carry added weight in rebuilding investor confidence. The combination of these two Phase III successes in NSCLC, a key therapeutic area for AstraZeneca, provided the primary boost for shares today, while the volrustomig setback served as a reminder of the inherent risks in late-stage drug development.
Overall, the stock experienced a meaningful but measured gain, reflective of the market balancing genuine pipeline progress against ongoing clinical and macro uncertainties.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
